TY - JOUR
T1 - Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis
AU - Haworth, C.S.
AU - Sharples, L.
AU - Hughes, V.
AU - Elkin, S.L.
AU - Hodson, M.E.
AU - Conway, S.P.
AU - Etherington, C.
AU - Elborn, J.S.
AU - Rendall, J.
AU - Wheaton, E.
AU - Kadri, E.
AU - Elliott, Jane
AU - Barker, H.C.
AU - Bearcroft, P.W.P.
AU - Hlaing, T.
AU - Compston, J.E.
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Background: The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods: Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35mg weekly or placebo, and calcium (1g)+vitamin D (800IU). Results: At baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24. months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24. months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (-0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p =0.41. Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.
AB - Background: The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods: Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35mg weekly or placebo, and calcium (1g)+vitamin D (800IU). Results: At baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24. months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24. months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (-0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p =0.41. Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-81455158920&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2011.07.007
DO - 10.1016/j.jcf.2011.07.007
M3 - Article
AN - SCOPUS:81455158920
SN - 1569-1993
VL - 10
SP - 470
EP - 476
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 6
ER -